Transcode Therapeutics, Inc.
RNAZ · XNASCIK 1829635fmd_0S5DGVMFS01Q6A0GK3DZ0KK8SMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 0 | 3 | 10 | 12 | 10 | 13 |
| Total operating expenses | 1 | 6 | 19 | 19 | 16 | 28 |
| Operating income | (1) | (6) | (19) | (19) | (16) | (28) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (2) | (1) | 1 | 1 | (1) | (6) |
| Income before taxes | – | – | – | – | (17) | (34) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (17) | (35) |
| Net income | (2) | (7) | (18) | (19) | (17) | (35) |
| Net income to common shareholders | – | – | – | (19) | (17) | (36) |